BioVaxys Technology Corp. (BVAXF)
- Previous Close
0.0590 - Open
0.0574 - Bid --
- Ask --
- Day's Range
0.0551 - 0.0600 - 52 Week Range
0.0091 - 0.0758 - Volume
67,844 - Avg. Volume
126,066 - Market Cap (intraday)
8.999M - Beta (5Y Monthly) 0.09
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms. It develops BVX-0320, a SARS-CoV-2 vaccine; BVX-1021, a vaccine for the strain of coronavirus that causes SARS1; and BVX-0918, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, a novel diagnostic platform to identify a T-cell immune response to the presence of SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions. It has a bioproduction agreement with WuXi Biologics Limited to produce SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; and research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320. BioVaxys Technology Corp. is based in Vancouver, Canada.
biovaxys.comRecent News: BVAXF
Performance Overview: BVAXF
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BVAXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BVAXF
Valuation Measures
Market Cap
8.78M
Enterprise Value
8.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.86
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.87
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.90%
Return on Equity (ttm)
-451.08%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.57M
Diluted EPS (ttm)
-0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
423
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.5M